Skip to Main Content

Despite periodic reports that biosimilars have finally arrived and will save the U.S. health care system billions of dollars, Peter Bach and Mark Trusheim remain unconvinced.

So the high-profile skeptics have refreshed their controversial, two-year-old argument for overhauling the approach for making alternative versions of pricey biologic medicines available to the American public.


Their basic premise remains the same: prices for brand-name biologic medicines should be based on production costs, and manufacturers should be given a fixed profit of 10% to 20% once the standard 12-year exclusive marketing period has ended. But to hammer home their point, they commissioned a report that indicates total savings could hit $360 billion by 2025, nearly four times what might otherwise be saved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!